ZIP7 is also associated with poor outcome in clinical breast cancer samples (253), consistent with a role in driving these aggressive growth pathways, yet it has also been deemed crucial for enabling the survival of breast cancer patients (254). Here, SLC39A7 is linked to breast cancer.